#### ![calendar-Icon](/themes/custom/cosmos/patterns/images/calendar-v2.svg)February 04, 2026

 

 #### Basel, Switzerland

 

 

 Novartis announces the company’s fourth quarter and 2025 full year financial results. 

 

 [    Press release  (282 KB)   ](https://prod1.novartis.com/sites/novartis_com/files/q4-2025-media-release-en.pdf) [    Pressemitteilung  (290 KB)   ](https://prod1.novartis.com/sites/novartis_com/files/q4-2025-media-release-de.pdf) 

 



 [    Condensed financial report  (452 KB)   ](https://prod1.novartis.com/sites/novartis_com/files/q4-2025-interim-financial-report-en.pdf) 

 



---

## Webcast and presentation

[Watch the webcast](https://edge.media-server.com/mmc/p/ceef8bnw)  
14:00 CET | 13:00 GMT | 08:00 EST

[Download the podcast (MP3 35 MB)](https://prod1.novartis.com/sites/novartis_com/files/2026-02/q4-2025-investor-presentation.mp3)



[Download the investor presentation (PDF 4.7 MB)](/sites/novartis_com/files/q4-2025-investor-presentation.pdf)

[Novartis Q4 2025 impact and sustainability update (PDF 1.0 MB)](https://prod1.novartis.com/sites/novartis_com/files/novartis-q4-2025-impact-and-sustainability-update.pdf)







---

 ![Business people walking on the Novartis Basel campus](/sites/novartis_com/files/styles/crop_freeform/public/2026-02/business-people-walking-on-novartis-basel-campus-banner.jpg.webp?itok=SGpMcZjg "Business people walking on the Novartis Basel campus")

 

### Annual Report 2025 and US Securities & Exchange Commission Form 20-F 2025

These reports provide a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial results, and compensation practices. They are filed with the SIX Swiss Exchange in Switzerland and the Securities and Exchange Commission in the US.

Novartis shareholders may receive a hard copy of either of these documents, each of which contains our complete audited financial statements, free of charge, upon request.

[Annual Report 2025 (PDF 3.1 MB)](/sites/novartis_com/files/novartis-annual-report-2025.pdf "novartis-annual-report-2025.pdf") | [Form 20-F 2025 (PDF 3.1 MB)](/sites/novartis_com/files/novartis-20-f-2025.pdf "novartis-20-f-2025.pdf")



### Report on Nonfinancial Matters 2025  


This report covers information on nonfinancial matters deemed material and in scope of our reporting obligations under the Swiss Code of Obligations (SCO), as well as our due diligence and reporting obligations in relation to child labor under the SCO.​

It includes our Human Rights Statement addressing specific jurisdictional requirements for disclosure on modern slavery, decent work, forced labor and child labor.​

[Download the report (PDF 1.0 MB)](/sites/novartis_com/files/novartis-report-nonfinancial-matters-2025.pdf "novartis-report-nonfinancial-matters-2025.pdf") | [HTML (ZIP 0.9 MB)](/sites/novartis_com/files/nvs-tcfd-2025-12-31.zip)









 



 [ 

 

###  Novartis Pipeline 

Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines.

 

 

 ](https://www.novartis.com/research-development/novartis-pipeline) [ 

 

###  Executive Committee of Novartis (ECN) biographies 

Under the leadership of Vasant Narasimhan, the Executive Committee of Novartis (ECN) is responsible for overseeing the business operations of Group companies.

 

 

 ](/about/executive-committee)